ranbaxy preview by centrum for Q2FY11

Visit http://indiaer.blogspot.com/ for complete details 􀂄 􀂄


Ranbaxy (Rating – Under Review)
􀂁 We expect the company to report net sales of Rs18.7bn.
􀂁 We expect a 320bps increase on a YoY basis in the EBIDTA margin to 16.1% owing to higher
sales from high margin formulations exports.
􀂁 Adjusted PAT is expected to grow by 42% to Rs1.9bn.